Recently the first AR NTD antagonist, a prodrug of EPI-002 [33,34], started Phase 1 clinical trials for prostate cancer patients that have failed abiraterone and/or enzalutamide (Clinical trials NCT02606123). Here, AR is linked to Familial prostate cancer.